Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer
This study is ongoing, but not recruiting participants.
Information provided by:
First received: July 26, 2007
Last updated: September 29, 2011
Last verified: September 2011
The purpose of this study is evaluate the treatment effect of panitumumab plus FOLFIRI as first line therapy in metastatic colorectal cancer.
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Single Arm Multicentre Phase II Study of Panitumumab in Combination With Irinotecan/5-fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Amgen:
|Study Start Date:||April 2007|
|Estimated Study Completion Date:||February 2012|
|Primary Completion Date:||June 2009 (Final data collection date for primary outcome measure)|
Drug: panitumumab and FOLFIRI
6mg/kg panitumumab (IV) on day 1 of each 14 day treatment cycle just prior to administration of chemotherapy (FOLFIRI). Number of cycles: until progression or unacceptable toxicity develops.
Other Name: Vectibix
Contacts and Locations